World-first gene therapy for a rare immune condition | Wellcome @wellcometrust
World-first gene therapy for a rare immune condition | Wellcome  @wellcometrust
Uploaded July 2026 | Updated November 2026, 1 day ago
Remi was diagnosed at two years old with chronic granulomatous disease (CGD), a rare condition that left his immune system unable to fight infection. Remi endured frequent illnesses and hospital visits. His childhood was shaped by the disease. At 16, his condition further worsened.

At Great Ormond Street Hospital, Claire Booth and her team were developing a gene therapy for CGD – adding a healthy copy of the gene to rebuild a working immune system. Remi became the first person in the world to receive the treatment. Since then, he has finished school, started university, and built relationships he once thought impossible.

This film is about the decades of research behind a single treatment – and the trust between families, clinicians and scientists that makes it possible.

Read the article: wellcome.org/insights/articles/gene-therapy-changing-future-people-rare-diseases

With thanks to Great Ormond Street Hospital, UCL Institute of Child Health, and the Zayed Centre for Research into Rare Disease in Children. Early research into p47-CGD gene therapy was supported by Wellcome, the CGD Society and Action Medical Research through funding to Adrian Thrasher and Georgia Santilli. The ongoing clinical trial is funded by the UCL Technology Fund (managed by AlbionVC) in collaboration with UCL Business.

Health Wonders is a series from Wellcome – changing lives through science.

wellcome.org/impact
World-first gene therapy for a rare immune condition | WellcomeJulia Gillard launches Lancet Countdown 2025Medics Advice for Summer | WellcomeHow extreme heat impacts pregnancy in Australia | WellcomeGood research needs good methodsWhat if snails were the key to solving a devastating tropical disease?The heat is on: Emilys story
Wellcome |

World-first gene therapy for a rare immune condition | Wellcome

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER